摘要
目的比较紫杉醇脂质体或紫杉醇联合替加氟、奥沙利铂治疗晚期胃癌的疗效和安全性。方法 62例初治的晚期胃癌患者分为紫杉醇脂质体组(A组,n=32)与紫杉醇组(B组,n=30),A组每周期予以紫杉醇脂质体135 mg·m^(-2),d 1,B组每周期予以紫杉醇135 mg·m^(-2),d 1,2组均联合替加氟500 mg·m^(-2),d 1～5,奥沙利铂130 mg·m^(-2),d 1。21 d为一个周期,2周期后评价疗效及安全性。结果 62例患者中有58例可评价疗效。A组总有效率47%,临床控制率为73%,B组总有效率46%,临床控制率71%,2组比较差异无显著意义(P>0.05),2组血液学毒性与神经毒性的发生率比较差异无显著意义(P>0.05),但A组的恶心、呕吐及过敏反应等的发生率明显低于B组(P<0.05)。结论紫杉醇脂质体或紫杉醇联合替加氟、奥沙利铂治疗晚期胃癌近期疗效相当,但过敏反应及胃肠道反应的发生率明显降低。
AIM To compare the efficacy and safety of paclitaxel liposome and paclitaxel combined with tegafur and oxaliplatin in the treatment of advanced gastric cancer. METHODS A total of 62 patients with advanced gastric cancer were recruited into this study, and divided into two groups. The patients in the group A were received paclitaxel liposome at a dose of 135 mg·m-2 on day 1 of each cycle, and the patients in the group B were received paclitaxel injection at a dose of 135 mg·m-2 on day 1 of each cycle. All patients were received tegafur at a dose of 500 mg·m-2 on day 1 - 5, and oxaliplatin at a dose of 130 mg·m-2 on day 1 for 2 cycles （each cycle was 21 d in total ）. RESULTS Fifty-eight patients could be evaluated for efficacy. The overall response rate was 47% in the group A, and 46% in the group B. Disease control rate was 73% in the group A, and 71% in the group B （P 〉 0,05） . There were no significant differences in hematologic and neurologic toxicity between two groups （P 〉 0.05 ）. However, nausea, vomiting and hypersensitive reactions in the group A were significantly lower than those in the group B （P 〈 0.05 ）. CONCLUSION Paclitaxel liposome is as effective as paclitaxel combined with tegafur and oxaliplation in the reactions. treatment of advanced gastric cancer with less adverse
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2011年第6期467-470,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
紫杉醇脂质体
紫杉醇
替加氟
奥沙利铂
胃肿瘤
治疗结果
药物不良反应
paclitaxel liposome
paclitaxel
＇tegafur
oxaliplatin
stomach neoplasms
treatment outcome
adverse drug reactions
